Literature DB >> 32971567

Mobility Device Use and Mobility Disability in U.S. Medicare Beneficiaries With and Without Cancer History.

Shirley M Bluethmann1, Eileen Flores1, Grace Campbell2, Heidi D Klepin3.   

Abstract

BACKGROUND/
OBJECTIVES: To examine the prevalence of mobility device use in U.S. community-dwelling older adults including older adults with cancer history ("survivors") and to estimate mobility disability noting variation by cancer history, cancer site, and other factors to improve early detection of mobility limitations.
DESIGN: Cross-sectional analysis from the 2011 National Health and Aging Trends Study.
SETTING: In-person interviews in the homes of study participants. PARTICIPANTS: Nationally representative sample of community-dwelling Medicare beneficiaries, aged 65 and older (n = 6,080 including 1,203 survivors). MEASUREMENTS: Participants were asked about cancer history, pain that limited activity, mobility device use (eg, canes, walkers, wheelchairs, and scooters), history of falls, and medical conditions plus they were assessed for approximate mobility disability using a 3-m gait speed test. The results were scored on a scale of 0 to 4 (0 = lowest, 4 = highest) using criteria from the National Institute on Aging.
RESULTS: A total of 19% of older adults and 23% of survivors reported using one or more mobility device, most commonly a single-point cane. Approximately 10% of breast, 6% of prostate, and 3% of colorectal cancer survivors reported using two or more devices in the past month. Survivors had lower mean gait speed scores (2.27) than adults without cancer history (2.39). In regression models, survivors were 18% less likely than adults without cancer history to score high on the gait speed test (odds ratio = .82; P < .05). Prior mobility device use, history of multiple falls, unhealthy weight, Black race, multimorbidity, and pain that limited activity were associated with lower gait speed scores in all participants (all P < .05).
CONCLUSION: A greater proportion of older survivors used mobility devices than adults without cancer history. Mobility device use varied by cancer site and was highest in survivors of breast, colorectal, and gynecological cancer. Survivors were also more likely to show signs of mobility disability, based on gait speed, compared with adults without cancer history. These indications, although modest, suggest that older survivors may require special attention to functional changes in survivorship.
© 2020 The American Geriatrics Society.

Entities:  

Keywords:  National Health and Aging Trends Study; cancer survivors; gait; mobility device; physical performance

Mesh:

Year:  2020        PMID: 32971567      PMCID: PMC8347693          DOI: 10.1111/jgs.16789

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  20 in total

Review 1.  The Underutilization of Rehabilitation to Treat Physical Impairments in Breast Cancer Survivors.

Authors:  Michael D Stubblefield
Journal:  PM R       Date:  2017-09       Impact factor: 2.298

2.  Translating weight loss and physical activity programs into the community to preserve mobility in older, obese adults in poor cardiovascular health.

Authors:  W Jack Rejeski; Peter H Brubaker; David C Goff; Lucille B Bearon; Jacquelyn W McClelland; Michael G Perri; Walter T Ambrosius
Journal:  Arch Intern Med       Date:  2011-01-24

3.  Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Kerri M Winters-Stone; Fay Horak; Peter G Jacobs; Phoebe Trubowitz; Nathan F Dieckmann; Sydnee Stoyles; Sara Faithfull
Journal:  J Clin Oncol       Date:  2017-06-06       Impact factor: 44.544

Review 4.  Geriatric assistive devices.

Authors:  Sara M Bradley; Cameron R Hernandez
Journal:  Am Fam Physician       Date:  2011-08-15       Impact factor: 3.292

5.  Impact of gait speed and instrumental activities of daily living on all-cause mortality in adults ≥65 years with heart failure.

Authors:  Alexander X Lo; John P Donnelly; Gerald McGwin; Vera Bittner; Ali Ahmed; Cynthia J Brown
Journal:  Am J Cardiol       Date:  2015-01-06       Impact factor: 2.778

6.  Mobility device use in older adults and incidence of falls and worry about falling: findings from the 2011-2012 national health and aging trends study.

Authors:  Nancy M Gell; Robert B Wallace; Andrea Z LaCroix; Tracy M Mroz; Kushang V Patel
Journal:  J Am Geriatr Soc       Date:  2015-05-06       Impact factor: 5.562

7.  Prevalence and impact of pain among older adults in the United States: findings from the 2011 National Health and Aging Trends Study.

Authors:  Kushang V Patel; Jack M Guralnik; Elizabeth J Dansie; Dennis C Turk
Journal:  Pain       Date:  2013-12       Impact factor: 6.961

Review 8.  Mobility devices to promote activity and participation: a systematic review.

Authors:  Anna-Liisa Salminen; Ase Brandt; Kersti Samuelsson; Outi Töytäri; Antti Malmivaara
Journal:  J Rehabil Med       Date:  2009-09       Impact factor: 2.912

9.  The detection and treatment of cancer-related functional problems in an outpatient setting.

Authors:  A L Cheville; L A Beck; T L Petersen; R S Marks; G L Gamble
Journal:  Support Care Cancer       Date:  2008-05-14       Impact factor: 3.603

10.  Added value of physical performance measures in predicting adverse health-related events: results from the Health, Aging And Body Composition Study.

Authors:  Matteo Cesari; Stephen B Kritchevsky; Anne B Newman; Eleanor M Simonsick; Tamara B Harris; Brenda W Penninx; Jennifer S Brach; Frances A Tylavsky; Suzanne Satterfield; Doug C Bauer; Susan M Rubin; Marjolein Visser; Marco Pahor
Journal:  J Am Geriatr Soc       Date:  2009-02       Impact factor: 5.562

View more
  1 in total

1.  Ambulatory Function and Mortality among Cancer Survivors in the NIH-AARP Diet and Health Study.

Authors:  Elizabeth A Salerno; Pedro F Saint-Maurice; Erik A Willis; Steven C Moore; Loretta DiPietro; Charles E Matthews
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-03-04       Impact factor: 4.090

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.